BDNF expression is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid from research suppliers |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are used fresh |
| Typical storage temperature | -20 °C for lyophilized powder | Short-term transport at 2-8 °C is common |
| Common analytical method | Reverse-phase HPLC | Paired with mass spectrometry for identity confirmation |
| Common synonyms | ACTH(4-10) analogue; MEHFPGP | N-terminal methionine retained in the chain |
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
Dissolution is normally performed in water, phosphate-buffered saline, or normal saline, since the peptide is freely soluble in aqueous media and is rarely handled with strong organic solvents. Solution pH should be kept near neutral, because extreme acidity or alkalinity accelerates backbone hydrolysis and encourages oxidation of the methionine side chain. Once dissolved, the material is less stable than the dry powder and is commonly divided into single-use portions and frozen. Buffers containing primary amines, such as Tris, are often avoided because of possible side reactions.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Such enthusiasm to use the Bryant Park name would have been nonexistent in the 1980s, when the area was described as "the Wild West". New real-estate developments were also built in the park's vicinity starting in the 21st century, which together added over 13,000 new workers to the area immediately surrounding Bryant Park. These included the Bank of America Tower; an expansion to 1095 Avenue of the Americas immediately to the south; Eleven Times Square a block west of Bryant Park; and 505 Fifth Avenue at Fifth Avenue and 42nd Street. Several hotels were also built, including a conversion of 485 Fifth Avenue at 41st Street, a Residence Inn by Marriott at Sixth Avenue and 39th Street. By the early 2010s, investors were purchasing buildings around Bryant Park south of 42nd Street as part of a small real estate boom. Rents per square foot in buildings south of 42nd Street had historically been lower than rents in buildings north of 42nd Street. Conversely, 1095 Avenue of the Americas and 452 Fifth Avenue were able to attract comparatively high rental rates despite both being south of 42nd Street. Later in the decade, the area around Bryant Park started growing into a residential neighborhood, with the construction of new developments in the area. Within a two-block radius of the park, or roughly 500 feet (150 m), units routinely sold for millions of dollars. By 2024, the Bryant Park Grill's lease was about to expire.
Fukuyama congenital muscular dystrophy (FCMD) is a rare, autosomal recessive form of muscular dystrophy (weakness and breakdown of muscular tissue) mainly described in Japan but also identified in Turkish and Ashkenazi Jewish patients; fifteen cases were first described on 1960 by Dr. Yukio Fukuyama.FCMD mainly affects the brain, eyes, and muscles, in particular, the disorder affects development of the skeletal muscles leading to weakness and deformed appearances, and brain development is blunted affecting cognitive functioning as well as social skills. In 1995, the disorder was linked to mutations in a gene coding for the protein fukutin (the FCMD gene). Fukuyama congenital muscular dystrophy is the second most prevalent form of muscular dystrophy in Japan. One out of every 90 people in Japan is a heterozygous carrier.
==== Porotic hyperostosis/cribra orbitalia ==== It was long assumed that iron deficiency anemia has marked effects on the flat bones of the cranium of infants and young children. That as the body attempts to compensate for low iron levels by increasing red blood cell production in the young, sieve-like lesions develop in the cranial vaults (termed porotic hyperostosis) and/or the orbits (termed cribra orbitalia). This bone is spongy and soft. It is however, unlikely that iron deficiency anemia is a cause of either porotic hyperostosis or cribra orbitalia. These are more likely the result of vascular activity in these areas and are unlikely to be pathological. The development of cribra orbitalia and porotic hyperostosis could also be attributed to other causes besides a dietary iron deficiency, such as nutrients lost to intestinal parasites. However, dietary deficiencies are the most probable cause. Anemia incidence may be a result of inequalities within society, and/or indicative of different work patterns and activities among different groups within society.
Sources: en.wikipedia.org
Hidden stops are non-stop codons that would be read as stop codons if they were frameshifted +1 or −1. These prematurely terminate translation if the corresponding frame-shift (such as due to a ribosomal RNA slip) occurs before the hidden stop. It is hypothesised that this decreases resource wastage on nonfunctional proteins and the production of potential cytotoxins. Researchers at Louisiana State University propose the ambush hypothesis, that hidden stops are selected for. Codons that can form hidden stops are used in genomes more frequently compared to synonymous codons that would otherwise code for the same amino acid. Unstable rRNA in an organism correlates with a higher frequency of hidden stops. However, this hypothesis could not be validated with a larger data set. Stop-codons and hidden stops together are collectively referred as stop-signals. Researchers at University of Memphis found that the ratios of the stop-signals on the three reading frames of a genome (referred to as translation stop-signals ratio or TSSR) of genetically related bacteria, despite their great differences in gene contents, are much alike. This nearly identical genomic-TSSR value of genetically related bacteria may suggest that bacterial genome expansion is limited by their unique stop-signals bias of that bacterial species.
=== Boers retreat === The set-piece period of the war now largely gave way to a guerrilla war, but one final operation remained. President Kruger and what remained of the Transvaal government had retreated to eastern Transvaal. Roberts, joined by troops from Natal under Buller, advanced against them, and broke their last defensive position at Bergendal on 26 August. As Roberts and Buller followed up along the railway line to Komatipoort, Kruger sought asylum in Portuguese East Africa (modern Mozambique). Some dispirited Boers did likewise, and the British gathered up much war material. However, the core of the Boer fighters under Botha easily broke back through the Drakensberg Mountains into the Transvaal highveld after riding north through the bushveld. As Roberts's army occupied Pretoria, the Boer fighters in the Orange Free State retreated into the Brandwater Basin, a fertile area in the south-east of the Republic. This offered only temporary sanctuary, as the mountain passes leading to it could be occupied by the British, trapping the Boers. A force under General Archibald Hunter set out from Bloemfontein to achieve this in July 1900. The hard core of the Free State Boers under De Wet, accompanied by President Steyn, left the basin early. Those remaining fell into confusion and most failed to break out before Hunter trapped them.
The disorder prediction category is a part of biannual CASP experiment that is designed to test methods according accuracy in finding regions with missing 3D structure (marked in PDB files as REMARK465, missing electron densities in X-ray structures). Disorder prediction can be more complicated for de novo-emerged and orphan proteins, which often lack detectable homologs and are generally shorter than "classical" proteins, reducing the reliability of predictors trained largely on conserved, globular proteins. Comparative benchmarks further show that structure/disorder predictors behave differently on de novo and random proteins than on conserved proteins, including different relationships between predicted disorder and confidence scores of 3D structure predictors, such as AlphaFold and ESMfold.
== History == Biocon was formed in 1978 as Biocon India Private Limited, an India-based partner to the existing Irish multinational brewing enzyme producer Biocon Biochemicals Ltd., with US$10,000 as startup capital from Mazumdar-Shaw. The subsidiary initially produced enzymes for the brewing market such as the papaya enzyme papain and the fish collagen extract Iisinglass, a clarifying agent used for some beers and wines. In 1979, Biocon became the first Indian company to manufacture and export enzymes to the US and Europe, and spent the 1980s producing an increasing share of pharmaceuticals for the domestic market.
Sources: en.wikipedia.org
== In plants == Approximately 30 GRX isoforms are described in the model plant Arabidopsis thaliana and 48 in Oryza sativa L. According to their redox-active centre, they are subgrouped in six classes of the CSY[C/S]-, CGFS-, CC-type and 3 groups with additional domains of unknown function. The CC-type GRXs are only found in higher plants. In Arabidopsis, GRXs are involved in flower development and Salicylic acid signalling.
== In philosophy == Gilbert Simondon invokes a notion of metastability for his understanding of systems that rather than resolve their tensions and potentials for transformation into a single final state rather, 'conserves the tensions in the equilibrium of metastability instead of nullifying them in the equilibrium of stability' as a critique of cybernetic notions of homeostasis.
== Career == Principal Scientist SCIEX - 1980-2005 Associate Professor (CLTA) at the University of Toronto, first in the Institute of Biomaterials and Biomedical Engineering (2005–2008) and then in Chemistry 2008–2013. President DVS Sciences 2004 - 2015 (acquired by Fluidigm in 2014) Adjunct Professor at York University in the Department of Chemistry 2015–2018
Sources: en.wikipedia.org
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.
A fraction of an intranasal dose is thought to reach the central nervous system, and this route is favoured partly for that reason. The proportion is not well characterized. Direct measurement in humans remains difficult with current methods.
Raised BDNF and NGF expression has been reported across several animal studies, which makes the signal fairly consistent. Whether the same change occurs in humans at usable doses is not established. It is best treated as a working hypothesis rather than a confirmed clinical mechanism.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.